Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
Previous Symbol
CUSIPN/A
Phone857-285-6200
Debt
Debt-to-Equity RatioN/A
Current Ratio11.53
Quick Ratio11.53
Price-To-Earnings
Trailing P/E Ratio-9.07
Forward P/E Ratio-8.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.12 million
Price / Sales28.36
Cash FlowN/A
Price / CashN/A
Book Value$6.06 per share
Price / Book2.82
Profitability
EPS (Most Recent Fiscal Year)($1.88)
Net Income$-67,540,000.00
Net Margins-308.81%
Return on Equity-31.70%
Return on Assets-25.84%
Miscellaneous
Employees195
Outstanding Shares43,420,000
Market Cap$711.21 million
OptionableOptionable
Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions
What is Intellia Therapeutics' stock symbol?
Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."
How were Intellia Therapeutics' earnings last quarter?
Intellia Therapeutics Inc (NASDAQ:NTLA) announced its earnings results on Wednesday, October, 31st. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.05. The company had revenue of $7.41 million for the quarter, compared to analysts' expectations of $11.58 million. Intellia Therapeutics had a negative net margin of 308.81% and a negative return on equity of 31.70%. The company's revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.44) earnings per share. View Intellia Therapeutics' Earnings History.
When is Intellia Therapeutics' next earnings date?
What price target have analysts set for NTLA?
9 Wall Street analysts have issued 12-month price targets for Intellia Therapeutics' shares. Their predictions range from $20.00 to $57.50. On average, they expect Intellia Therapeutics' share price to reach $36.8750 in the next twelve months. This suggests a possible upside of 116.1% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.
What is the consensus analysts' recommendation for Intellia Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intellia Therapeutics.
What are Wall Street analysts saying about Intellia Therapeutics stock?
Here are some recent quotes from research analysts about Intellia Therapeutics stock:
- 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (11/6/2018)
- 2. Cann analysts commented, "We believe ex-vivo therapies are a lower risk approach for use of CRISPR as therapeuitc, and while early stage, the AML program is an important program for Intellia. Data presented today at ESGCT continue to support this discovery phase program. Data presented today for the NTLA-1001 ATTR program are consistent with data presented in August 2018 and support the high efficiency of Intellia’s NTLA-1001 CRISPR/Cas9 guide and lipid nanoparticle delivery in non-human primate models. Our outlook for Intellia remains unchanged, and we continue to expect an IND for NTLA-1001 in ATTR by the end of 2019, and are encouraged by the AML program." (10/18/2018)
- 3. Chardan Capital analysts commented, "We note Intellia is collaborating with the same research group at the Saraiva, who worked with Alnylam during the preclinical development of its RNAi-based therapeutics to treat ATTR. In 2010, Alnylam presented preclinical data (1, 2), also using the Porto group’s transgenic V30M mouse model, showing reductions of TTR deposition of >95% after siRNA administration every 2 weeks. Importantly, with 1 siRNA dose, TTR protein levels began to rebound within 8 days after treatment. In contrast, 1 dose of Intellia’s LNP-delivered CRISPR/Cas agent resulted in stable knockdown over 12 months, underscoring the potential advantage of the permanent nature of gene editing, though more durable RNAi formulations are now in development." (8/24/2018)
Has Intellia Therapeutics been receiving favorable news coverage?
Media stories about NTLA stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intellia Therapeutics earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Intellia Therapeutics' key competitors?
Some companies that are related to Intellia Therapeutics include Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV) and Arca Biopharma (ABIO).
Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the folowing people:
- Dr. John M. Leonard, Pres, CEO & Director (Age 61)
- Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 45)
- Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 52)
- Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 32)
- Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
When did Intellia Therapeutics IPO?
(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Intellia Therapeutics' major shareholders?
Intellia Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.25%), BlackRock Inc. (6.32%), FMR LLC (5.67%), Morgan Stanley (4.54%), Chevy Chase Trust Holdings Inc. (1.71%) and Rehmann Capital Advisory Group (0.95%). Company insiders that own Intellia Therapeutics stock include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.
Which major investors are selling Intellia Therapeutics stock?
NTLA stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Morgan Stanley, Tekla Capital Management LLC, FMR LLC, Man Group plc, Great West Life Assurance Co. Can, United Services Automobile Association and DekaBank Deutsche Girozentrale. Company insiders that have sold Intellia Therapeutics company stock in the last year include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard and Nessan Bermingham. View Insider Buying and Selling for Intellia Therapeutics.
Which major investors are buying Intellia Therapeutics stock?
NTLA stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Rehmann Capital Advisory Group, BlackRock Inc., Greenwoods Asset Management Ltd, Chevy Chase Trust Holdings Inc., First Trust Advisors LP, Dimensional Fund Advisors LP and Allianz Asset Management GmbH. View Insider Buying and Selling for Intellia Therapeutics.
How do I buy shares of Intellia Therapeutics?
Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intellia Therapeutics' stock price today?
One share of NTLA stock can currently be purchased for approximately $17.06.
How big of a company is Intellia Therapeutics?
Intellia Therapeutics has a market capitalization of $725.10 million and generates $26.12 million in revenue each year. The company earns $-67,540,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Intellia Therapeutics employs 195 workers across the globe.
What is Intellia Therapeutics' official website?
How can I contact Intellia Therapeutics?
Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]
MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
